ViiV Healthcare’s investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial. In the EMBRACE trial (NCT05996471), lotivibart, a broadly neutralising antibody, ...
The therapy is constructed by the insertion of TCF4 isoform B into an AAV9 expression cassette. Credit: Stock-Asso / Shutterstock.com. Mahzi Therapeutics has dosed the first patient in its Phase I/II ...
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
Jaguar Gene Therapy has completed Cohort I dosing of its first-in-human clinical trial investigating JAG201 for patients with SHANK3 haploinsufficiency.
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...
This report follows a number of initiatives in the EU that are trying to make it a more attractive region for research. Image credit: Vladimir Sukhachev / Shutterstock.com A further €4bn ($4.72bn) a ...
The Phase I/IIa study evaluates six-month dosing over 12 months for safety, tolerability, pharmacodynamic and pharmacokinetics effects. Credit: PhotobyTawat / Shutterstock.com. Vico Therapeutics has ...
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.
Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with PAH.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results